RVNC News & Events

Aeon Biopharma (AEON) announced the appointment of Rob Bancroft as president and CEO, effective April 29. Bancroft will also join Aeon's board of directors. Bancroft brings over 25 years of experience in the life sciences industry, spanning biopharmaceuticals, medical devices, and healthcare technology. Prior to joining Aeon he served as GM of the therapeutics business at Revance (RVNC).

Crown Laboratories announced the closing of its acquisition of Revance Therapeutics. Crown's tender offer to acquire all of the issued and outstanding shares of common stock, par value 0.1c per share of Revance at a purchase price of $3.65 per Share, expired as scheduled on February 4 and was not further extended. 86,197,893 Shares were validly tendered and not properly withdrawn in the Offer, representing approximately 82.0% of the issued and outstanding Shares as of the Expiration Time. Following completion of the Offer, Crown completed the acquisition of Revance through the second-step merger. Revance's common stock will be delisted from the NASDAQ Global Select Market and deregistered under the Securities Exchange Act of 1934.

Revance and Crown Laboratories reminded Revance stockholders of the recommendation to tender their shares in support of Crown's cash tender offer to acquire all of the issued and outstanding shares of common stock, par value 0.1c per share of Revance, at a price of $3.65 per Share in cash before the expiry of the tender offer at one minute past 11:59 p.m., Eastern Time, on February 4, 2025. The Crown tender offer of $3.65 per share in cash, which has been unanimously recommended by Revance's board, is the only offer available to Revance stockholders. Teoxane has withdrawn its non-binding proposal to acquire Revance and intends to tender all of its Shares, representing a 6.2% stake, in the tender offer. Revance stockholders must tender by the February 4 deadline for the transaction to close. Crown does not intend to extend the outside termination date of the A&R Merger Agreement. Subject to customary closing conditions, including the tender of more than 50% of the Shares into the tender offer, the transaction is expected to close by February 6.